Aerie Pharmaceuticals - AERI Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AERI shares.
View AERI analyst ratings or view top-rated stocks.

2 analysts have issued twelve-month price targets for Aerie Pharmaceuticals' shares. Their AERI share price forecasts range from $14.00 to $29.00. On average, they expect the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 78.1% from the stock's current price.
View analysts price targets for AERI or view top-rated stocks among Wall Street analysts.

Aerie Pharmaceuticals' stock was trading at $7.02 at the start of the year. Since then, AERI stock has increased by 64.0% and is now trading at $11.51.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AERI earnings forecast.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its earnings results on Thursday, August, 4th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.20. During the same period in the prior year, the firm earned ($0.67) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (3.79%), Pinnacle Associates Ltd. (2.13%), Deutsche Bank AG (2.03%), Walleye Capital LLC (1.30%), FMR LLC (1.18%) and Granite Investment Partners LLC (0.96%). Insiders that own company stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends.

Shares of AERI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AERI stock can currently be purchased for approximately $11.51.

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $568.13 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

The company employs 376 workers across the globe.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787.